NEXAVAR® (sorafenib) in locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine therapy

Progression-free survival (PFS) results

In DECISION, NEXAVAR demonstrated a median PFS of 10.8 months (95% CI, 9.1-12.9) vs 5.8 months (95% CI, 5.3-7.8) with placebo (HR=0.59; 95% CI, 0.46-0.76; P<0.001).1

DECISION study: Median PFS1
Median progression-free survival data for NEXAVAR® (sorafenib)
41%

reduction in risk of disease progression or death (PFS) with NEXAVAR vs placebo1,2

HR: 0.59; 95% Cl, 0.46-0.76; P<0.001

DECISION (StuDy of sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine-refractory thyrOid caNcer) study: A randomized, double-blind, placebo-controlled, multicenter study in patients with locally recurrent or metastatic, progressive, DTC refractory to RAI (N=417).1

41%

reduction in risk of disease progression or death (PFS) with NEXAVAR vs placebo1,2

HR: 0.69; 95% Cl, 0.46-0.76; P<0.001

DECISION (StuDy of sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine-refractory thyrOid caNcer) study:

A randomized, double-blind, placebo-controlled, multicenter study in patients with locally recurrent or metastatic, progressive,

DTC refractory to RAI (N=417).1

  • NEXAVAR nearly doubled progression-free survival (PFS)1

  • Death or progression occurred in 113 (55%) of patients in the NEXAVAR arm and 136 (65%) in the placebo arm1